Chemotherapy: which drug and when?
Alberto F. Sobrero(Ospedale Policlinico San Martino), E. Bennicelli(Ospedale Policlinico San Martino)
Cited by 7
Related Papers
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
|The Lancet. Gastroenterology & hepatology|2020|249
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
|The Oncologist|2018|144
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
|Journal for ImmunoTherapy of Cancer|2019|140
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial
|Annals of Oncology|2010|110